Feyzullah Aksan, MD

Renaissance School of Medicine, Stony Brook University

Poster(s):

• P0625 - Sex-specific Response Patterns to Tricyclic Antidepressants in Patients With Diarrhea-Predominant Irritable Bowel Syndrome: A Propensity-Matched, Retrospective Cohort Study
  Sunday, October 27, 2024

  3:30 PM – 7:00 PM ET

• P0858 - Comparing Ustekinumab and Vedolizumab in Inflammatory Bowel Disease Patients Exposed to Anti-TNF Agents: A Propensity-Matched, Retrospective Cohort Study
  Sunday, October 27, 2024

  3:30 PM – 7:00 PM ET

• P0859 - Impact of Body Mass Index on the Effectiveness of Biologic Therapies in Inflammatory Bowel Disease: A Retrospective, Propensity Score-Matched Cohort Study
  Sunday, October 27, 2024

  3:30 PM – 7:00 PM ET

• P0860 - Ustekinumab Monotherapy vs Ustekinumab Combined with Immunomodulators in Inflammatory Bowel Disease: A Propensity-Matched, Retrospective Cohort Study
  Sunday, October 27, 2024

  3:30 PM – 7:00 PM ET

• P0861 - Continuing or Discontinuing Mesalamine in Crohn’s Disease? A Multinational, Propensity-Matched, Retrospective Cohort Study
  Sunday, October 27, 2024

  3:30 PM – 7:00 PM ET

• P0862 - Vedolizumab Monotherapy Vs Vedolizumab Combined with Immunomodulators in Inflammatory Bowel Disease: A Propensity-Matched, Retrospective Cohort Study
  Sunday, October 27, 2024

  3:30 PM – 7:00 PM ET

• P0863 - Comparing the Risk of Venous Thromboembolism and Pulmonary Embolism in Inflammatory Bowel Disease Patients Treated With Different Biologics: A Propensity Score-Matched, Retrospective Cohort Study
  Sunday, October 27, 2024

  3:30 PM – 7:00 PM ET